Hoechst Pakistan Limited (PSX:HPL)

Pakistan · Delayed Price · Currency is PKR

4,150.04

+77.04 (1.89%)

At close: Aug 20, 2026

8.34% (1Y)

Market Cap	39.28B +6.3%
Revenue (ttm)	31.08B +10.9%
Net Income	3.06B +47.4%
EPS	317.04 +47.4%
Shares Out	9.64M
PE Ratio	12.85
Forward PE	n/a
Dividend	240.00 (6.00%)
Ex-Dividend Date	Apr 1, 2026

Volume	8,044
Open	4,073.01
Previous Close	4,073.00
Day's Range	3,966.40 - 4,240.00
52-Week Range	3,602.00 - 4,889.99
Beta	0.24
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Hoechst Pakistan

Hoechst Pakistan Limited, together with its subsidiary, manufactures, sells, and trades in pharmaceutical and related products in Pakistan, Afghanistan, and internationally. The company offers allergy management, anti-diarrheals, antibiotics, antiemetic, cardiology, consumer healthcare, diabetes, neurology, and emergency care products under various brand names, as well as vaccines. It exports its products. The company was formerly known as Sanofi-Aventis Pakistan Limited and changed its name to Hoechst Pakistan Limited in September 2023. Hoechs... [Read more]

Industry Pharmaceutical Preparations

Founded 1967

Employees 957

Stock Exchange Pakistan Stock Exchange

Ticker Symbol HPL

Full Company Profile

Financial Performance

In 2025, Hoechst Pakistan's revenue was 30.96 billion, an increase of 15.73% compared to the previous year's 26.75 billion. Earnings were 2.90 billion, an increase of 56.16%.

Financial Statements